Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.8%.
The iShares Biotechnology ETF (IBB) advanced 0.7%.
In corporate news, Veru (VERU) said Monday it has completed enrollment in a phase 2 trial evaluating its experimental drug enobosam in combination with semaglutide, in about 200 adults aged 65 and older with obesity. Veru shares gained 4.9%.